For an adult patient with episodic or chronic migraine needing preventive therapy, should I choose rimegepant (75 mg oral daily) or erenumab (70 mg/140 mg subcutaneous monthly)?

Rimegepant vs Erenumab for Migraine Prevention

For migraine prevention in adults, start with rimegepant 75 mg every other day before erenumab, primarily due to cost considerations and patient preference for oral administration, as both agents demonstrate similar efficacy but rimegepant offers the convenience of oral dosing. 1

Guideline-Based Treatment Algorithm

The 2025 American College of Physicians clinical guideline provides clear direction on CGRP-targeted therapy selection 1:

First-Line Approach

• Try traditional preventives first: β-blockers (metoprolol/propranolol), valproate, venlafaxine, or amitriptyline
• Cost is the primary differentiator between CGRP antagonists, as they show similar net clinical benefits
• Patient preference matters: Oral medications (gepants like rimegepant) are preferred over injectables (monoclonal antibodies like erenumab) based on values and preferences data 1

When to Use CGRP-Targeted Therapies

Consider rimegepant or erenumab after:

• Inadequate response to traditional preventives (2-3 month trial)
• Intolerable adverse effects from traditional agents
• Contraindications to first-line options

Choosing Between Rimegepant and Erenumab

Rimegepant advantages:

• Oral administration (75 mg every other day) - preferred by patients 1
• Dual indication: Can also treat acute attacks 2
• Lower cost compared to monoclonal antibodies (though still expensive) 1
• Efficacy: Reduces monthly migraine days by 4.3 days vs 3.5 with placebo (difference -0.8 days, p=0.010) 2
• Responder rate: 49.1% achieve ≥50% reduction in migraine days 2

Erenumab considerations:

• Monthly subcutaneous injection (70 mg or 140 mg) 3
• Slightly higher efficacy in head-to-head indirect comparison: erenumab 140 mg showed 1.28 additional migraine day reduction vs rimegepant at month 3 4
• More expensive than rimegepant 1
• Injection-based - less preferred by patients 1

Clinical Decision Framework

Choose rimegepant when:

• Patient prefers oral medication
• Cost is a significant concern
• Patient needs both acute and preventive treatment
• Patient has episodic migraine (average 10 migraine days/month)

Choose erenumab when:

• Patient has failed rimegepant trial
• Patient prefers monthly dosing over every-other-day
• Adherence concerns with frequent oral dosing
• Insurance covers erenumab preferentially

Efficacy Comparison

While both are effective, the clinical differences are modest 4:

• Rimegepant reduces monthly migraine days by ~4.3 days from baseline 2, 5
• Erenumab 140 mg reduces monthly migraine days by ~5.5 days from baseline (approximately 1.3 days more than rimegepant) 4
• Both show similar tolerability profiles with adverse event rates comparable to placebo 5, 6

Safety Profile

Both agents are well-tolerated:

• Rimegepant: 36% adverse event rate (same as placebo), most common are nausea and upper respiratory infection 5
• Erenumab: Injection site reactions and constipation are most common (≥3%); serious constipation complications can occur 3
• Important erenumab warning: Can cause new-onset or worsening hypertension 3

Practical Implementation

Rimegepant dosing 2:

• 75 mg orally disintegrating tablet every other day
• Can also use 75 mg as needed for acute attacks (not to exceed 18 doses/month)
• Start at low dose if needed, though 75 mg is standard

Erenumab dosing 3:

• Start with 70 mg subcutaneously monthly
• Can increase to 140 mg monthly if inadequate response
• Administer in abdomen, thigh, or upper arm

Common Pitfalls to Avoid

1. Don't skip traditional preventives: The guideline explicitly recommends trying β-blockers, valproate, venlafaxine, or amitriptyline first unless contraindicated 1

2. Don't expect immediate results: Allow 2-3 months for adequate trial before declaring treatment failure 1

3. Don't ignore cost: CGRP antagonists are substantially more expensive than traditional preventives; assess patient's economic circumstances 1

4. Don't combine two CGRP preventives routinely: While emerging data suggests dual CGRP therapy may benefit select refractory patients, this remains investigational with potential stroke risk 7

5. Monitor for constipation with erenumab: Serious complications can occur 3

6. Screen for cardiovascular risk with erenumab: Contraindicated in recent MI, stroke, or serious cardiovascular events 3

Special Populations

Women of childbearing potential: Discuss pregnancy risks with both agents; safety data in pregnancy are limited 1, 2

Chronic migraine (≥15 headache days/month): Both agents have evidence in chronic migraine, though this guideline focused on episodic migraine 8, 9